These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
164 related articles for article (PubMed ID: 36274045)
1. Changes in exercise endurance and inspiratory capacity after lumacaftor/ivacaftor therapy in cystic fibrosis. Savi D; Gramegna A; Vicenzi M; Di Paolo M; Messore B; Palange P; Blasi F Pulmonology; 2023; 29(4):338-341. PubMed ID: 36274045 [No Abstract] [Full Text] [Related]
2. Response to: 'Lumacaftor/ivacaftor for patients homozygous for Phe508del-CFTR: should we curb our enthusiasm?' by Jones and Barry. Elborn JS; Ramsey B; Wainwright C; Boyle M Thorax; 2016 Feb; 71(2):185-6. PubMed ID: 26506855 [No Abstract] [Full Text] [Related]
3. Lumacaftor/ivacaftor for patients homozygous for Phe508del-CFTR: should we curb our enthusiasm? Jones AM; Barry PJ Thorax; 2015 Jul; 70(7):615-6. PubMed ID: 26071414 [No Abstract] [Full Text] [Related]
4. Successful Pregnancy of a Patient with Cystic Fibrosis Genotype F508del/ F508del and Progressed Pulmonary Destruction on lumacaftor/ivacaftor. Mainz JG; Michl RK; Beiersdorf N; Lorenz M; Schneider U; Groten T; Jaudszus A Klin Padiatr; 2019 Sep; 231(5):271-273. PubMed ID: 31408905 [No Abstract] [Full Text] [Related]
6. Lumacaftor/ivacaftor (Orkambi) for cystic fibrosis. Med Lett Drugs Ther; 2016 Mar; 58(1491):41-2. PubMed ID: 27027688 [No Abstract] [Full Text] [Related]
7. A Review on the Use of Cystic Fibrosis Transmembrane Conductance Regulator Gene Modulators in Pediatric Patients. Bitonti M; Fritts L; So TY J Pediatr Health Care; 2019; 33(3):356-364. PubMed ID: 31029283 [TBL] [Abstract][Full Text] [Related]
8. Lumacaftor/ivacaftor combination therapy for cystic fibrosis: A nationwide survey among clinicians. Casciaro R; Costa S; Dang P; Majo F; Ros M Clin Respir J; 2018 Apr; 12(4):1767-1768. PubMed ID: 28759146 [No Abstract] [Full Text] [Related]
9. Change in exercise capacity measured by Cardio-pulmonary Exercise Testing (CPET) in Danish people with cystic fibrosis after initiation of treatment with Lumacaftor/Ivacaftor and Tezacaftor/Ivacaftor. Rysgaard UK; Pedersen CL; Jensen JH; Sørensen L; Philipsen LKD; Leo-Hansen C; Olesen HV J Cyst Fibros; 2022 Sep; 21(5):844-849. PubMed ID: 35667973 [TBL] [Abstract][Full Text] [Related]
10. A new era in the treatment of cystic fibrosis. Lane MA; Doe SJ Clin Med (Lond); 2014 Feb; 14(1):76-8. PubMed ID: 24532752 [No Abstract] [Full Text] [Related]
11. Continuous glucose monitoring in youth with cystic fibrosis treated with lumacaftor-ivacaftor. Li A; Vigers T; Pyle L; Zemanick E; Nadeau K; Sagel SD; Chan CL J Cyst Fibros; 2019 Jan; 18(1):144-149. PubMed ID: 30104123 [TBL] [Abstract][Full Text] [Related]
14. A combination therapy for cystic fibrosis. Brodsky JL; Frizzell RA Cell; 2015 Sep; 163(1):17. PubMed ID: 26406363 [TBL] [Abstract][Full Text] [Related]
15. Comparison of Organoid Swelling and Graeber SY; van Mourik P; Vonk AM; Kruisselbrink E; Hirtz S; van der Ent CK; Mall MA; Beekman JM Am J Respir Crit Care Med; 2020 Dec; 202(11):1589-1592. PubMed ID: 32687398 [No Abstract] [Full Text] [Related]